SIGN IN
Attaining Excessive-Titer Bispecific Antibody Manufacturing with >98% Heterodimer Purity
Bispecific antibodies (bsAbs) characterize a major development in biologic therapeutics. Nonetheless, their improvement poses key challenges, comparable to the necessity for intensive pairing screening to establish the optimum ones and addressing low yield and purity throughout manufacturing. Every bsAb format additionally presents distinctive complexities within the manufacturing course of.
This white paper introduces revolutionary methods to deal with these challenges, from high-throughput, small-scale manufacturing for optimum pairing identification, to overcoming distinctive challenges throughout numerous codecs like CrossMab, ScFv-Fab, and extra. By leveraging revolutionary approaches, we obtain high-titer CHO manufacturing of bsAbs with >98% heterodimer purity and endotoxin degree <0.1 EU/mg.
Obtain this white paper to find:
1. Modern manufacturing platforms enabling fast and cost-effective identification of optimum bsAb pairings.
2. Tailor-made options for various bsAb codecs, leveraging LC-MS assisted purification to realize >98% heterodimer purity.
3. HC/LC chain ratio optimization to enhance each titer and purity.
Trending Merchandise
